Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | PKM | P14618 | 9/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7077235 | 0.86 | KMT2A (0.63) | KMT2APKMALDH1A1RAB9APOLB | |
| Acetic Acid SCHEMBL27550400 | 0.84 | KMT2A (0.58) | KMT2APKMALDH1A1RAB9APOLB | |
| SCHEMBL18711517 | 0.81 | PKM (0.73) | KMT2APKMALDH1A1RAB9APOLB | |
| SCHEMBL10726980 | 0.79 | LMNA (0.81) | KMT2AALDH1A1CA9MEN1 | |
| SCHEMBL5322126 | 0.79 | GCKR (0.51) | KMT2APKMALDH1A1RAB9APOLB | |
| SCHEMBL7075345 | 0.78 | KMT2A (0.56) | KMT2APKMALDH1A1RAB9APOLB | |
| SCHEMBL30754639 | 0.78 | PKM (0.67) | KMT2APKMALDH1A1POLB | |
| SCHEMBL28819251 | 0.78 | PKM (0.67) | KMT2APKMALDH1A1 | |
| SCHEMBL18701940 | 0.78 | PKM (0.67) | KMT2APKMALDH1A1RAB9APOLB | |
| SCHEMBL31538999 | 0.77 | KMT2A (0.64) | KMT2APKMALDH1A1RAB9ACA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10028992-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028992-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2018-07-24 | — | — | US | disclosed |
| US-20150290276-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY | 2015-10-15 | — | — | US | disclosed |
| US-20150290276-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290276-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | ITGB7, ITGA2B, ITGB1 | KMT2A 3360/4885PKM 2377/4885ALDH1A1 342/4885 |
| US-10028992-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | KMT2A 3360/4885PKM 2377/4885ALDH1A1 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.